Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Insurance coverage sits at the center of this dementia and brain health question.
Insurance coverage gaps are forcing families to delay critical neurological care at a time when early intervention could prevent permanent disability. The root cause is multifaceted: premiums have doubled for millions after the end of enhanced ACA subsidies in 2025 (affecting 22 million people), denial rates for advanced imaging procedures used in neurological diagnosis have reached 24% on average, and “medical necessity” challenges now block nearly half of all advanced imaging claims. Families find themselves rationing appointments with specialists, postponing diagnostic tests, and attempting to manage conditions like early-onset dementia, Parkinson’s disease, and stroke recovery without proper medical oversight. This article examines how insurance barriers are delaying diagnosis and treatment, the costs of these delays, and what families can do when coverage denials threaten their neurological health.
Table of Contents
- How Insurance Denials Are Blocking Neurological Diagnosis
- The Affordability Crisis That Prevents Initial Doctor Visits
- Specific Impact on Dementia and Cognitive Decline Detection
- Why Out-of-Network Care Often Backfires
- The Compounding Costs of Delayed Neurological Care
- Coverage Gaps in Specialized Neurological Therapies
- Advocacy and Future Changes in Insurance Coverage
- Conclusion
- Frequently Asked Questions
How Insurance Denials Are Blocking Neurological Diagnosis
The barrier to neurological care often begins before treatment even starts—at the diagnostic stage. Advanced imaging like MRI and PET scans, essential tools for detecting dementia, stroke, and other brain conditions, face denial rates of 24%, significantly higher than the 12% average for other diagnostic procedures. When insurers invoke “medical necessity” challenges—which account for 47% of advanced imaging denials—they’re essentially requiring your neurologist to prove that the scan is absolutely essential before your plan will pay. This creates a Catch-22: your doctor may need the imaging results to diagnose your condition, but insurance won’t cover it until they can prove you need it. One patient with progressive cognitive decline was denied an MRI three times over six months while her neurologist filed appeals, during which her condition deteriorated further.
By the time approval came, additional testing was needed because the early window for intervention had closed. The problem extends beyond imaging to overall claim denials. Insurance companies deny 19% of claims for in-network services and 37% of out-of-network claims. For neurological conditions that require specialist input, this creates a compounding problem: if your in-network neurologist’s diagnostic request is denied, seeking a second opinion out-of-network faces even steeper denial odds. Families report spending weeks or months in appeal processes while symptoms progress untreated.
The Affordability Crisis That Prevents Initial Doctor Visits
Before families even reach the insurance denial stage, many are failing to schedule neurological appointments because they can no longer afford the out-of-pocket costs. The enhanced subsidies under the Affordable Care Act—which had helped approximately 22 million people afford marketplace health insurance—expired at the end of 2025. For the average person, this means premiums have more than doubled in 2026. Families making modest middle-class incomes suddenly found themselves priced out of adequate coverage, leading many to delay or skip routine neurology consultations, memory screenings, and follow-up appointments.
A family earning $60,000 annually might have paid $200 monthly for coverage in 2025; by early 2026, that same plan cost over $500, forcing choices between insurance and other basic needs. However, there’s an important distinction: even for those who maintain insurance, the problem isn’t always unaffordable premiums but rather high deductibles paired with denial rates that prevent claims from being paid. Some families discovered that their new 2026 plans had $6,000 or $7,000 deductibles with narrow networks, meaning they pay full price for specialist visits until the deductible is met, and even then, imaging requests face the denial barriers described above. This creates a dual barrier—cost of access plus cost of denial appeals.
Specific Impact on Dementia and Cognitive Decline Detection
Dementia diagnosis depends heavily on timely cognitive testing and neuroimaging, both services vulnerable to insurance delays. The early stages of dementia are often subtle—a family member notices increasing forgetfulness or difficulty managing finances, but these symptoms are easy to dismiss as normal aging. By the time families seek a neurology evaluation, insurance barriers can delay the diagnostic process by months or even years.
Without an early diagnosis, patients miss the critical window for medications like aducanumab or lecanemab, which show effectiveness in slowing cognitive decline but only work in early stages. One family postponed their mother’s neurologist appointment for four months because of out-of-pocket cost concerns, only to discover during evaluation that her cognitive decline had progressed significantly, moving her beyond the eligibility window for disease-modifying treatments. Beyond individual cases, the broader economic impact is staggering. The economic burden of major neurologic diseases approaches $800 billion annually in the United States, and delayed diagnosis contributes substantially to this cost through preventable complications, hospitalizations, and reduced quality of life.
Why Out-of-Network Care Often Backfires
When in-network neurologists can’t help or have months-long wait times, families are tempted to seek out-of-network specialists. However, this frequently amplifies insurance problems rather than solving them. Out-of-network claims face denial rates of 37%, compared to 19% for in-network services. An out-of-network neurologist’s diagnostic imaging request carries higher denial risk and produces out-of-pocket bills that can reach thousands of dollars.
One family paid $4,500 out of pocket for an out-of-network MRI and accompanying neurologist consultation only to have insurance deny the claim for “lack of pre-authorization,” leaving them with the full bill despite having insurance. The tradeoff is stark: stay in-network and risk long waits or limited options, or go out-of-network and risk both denial and substantial out-of-pocket costs. Pre-authorization requirements add another layer of complexity. While pre-authorization is supposed to confirm coverage before a service is rendered, many families discover too late that the authorization granted by one insurance representative is contested by another during claims review. The solution is to request pre-authorization in writing and retain copies of all correspondence—a step many patients miss until after bills arrive.
The Compounding Costs of Delayed Neurological Care
The financial consequences of delaying neurological care extend far beyond the initial diagnostic visit. Patients with functional neurological disorders and other brain conditions often experience delayed diagnosis by years, which results in preventable costs including missed work, repeated medical consultations with providers who misdiagnose the condition, and unnecessary investigations for unrelated causes. A patient with Parkinson’s disease who delayed diagnosis due to insurance barriers may have spent two years visiting emergency rooms for falls, orthopedic consultations for suspected spinal issues, and psychiatry evaluations for depression—all while the actual neurological disease progressed untreated.
The cumulative cost of these misdirected treatments often exceeds the cost of early diagnosis and appropriate care. Evidence shows that increased access to specialist neurological care actually reduces overall healthcare costs and improves outcomes, yet insurance structures create the opposite incentive. When insurance denies specialist referrals and diagnostic imaging, it may reduce short-term claim payouts but increases long-term costs through complications, hospitalizations, and emergency care that result from delayed diagnosis.
Coverage Gaps in Specialized Neurological Therapies
Beyond diagnosis, families face another coverage problem: specialized neurological therapies often lack transparent coverage policies. A 2025 study found that health plans show significant lack of transparency and policy availability in covering neuromuscular disease therapies.
Many plans provide generic policies that don’t clearly state what therapies are covered or at what stage of disease, creating uncertainty for families already dealing with frightening diagnoses. Worse, for conditions where therapy timing is critical—such as stroke rehabilitation or early Parkinson’s treatment—delays in authorization while insurers review coverage policies can compromise treatment effectiveness. One family learned that their plan didn’t clearly cover occupational therapy for post-stroke recovery only after their insurance company requested that the therapy be discontinued after six weeks, despite the patient still being in the critical recovery window where intensive therapy produces the best outcomes.
Advocacy and Future Changes in Insurance Coverage
Several states have begun implementing protections against the worst insurance coverage gaps in neurological care, including surprise billing protections and requirements for transparent coverage policies on specialized therapies. However, federal policy has yet to establish consistent standards for neurological diagnostic coverage across plans.
The data showing that increased access to specialist neurological care reduces healthcare costs and improves outcomes should, in theory, incentivize insurance companies to improve coverage, but the current fee-for-service system often rewards denials over approval. Looking ahead, families and patients are increasingly advocating for coverage standards that address the specific needs of neurological conditions, where early diagnosis genuinely changes outcomes. Changes may come through state-level legislation, patient advocacy by organizations like the Alzheimer’s Association and American Academy of Neurology, or through market pressure as more families recognize that insurance barriers to neurological care ultimately increase total healthcare costs.
Conclusion
Insurance coverage gaps are imposing real delays on critical neurological care, forcing families to choose between paying for coverage they can’t afford or attempting to manage serious brain conditions without proper diagnosis and specialist guidance. The combination of expired ACA subsidies, high denial rates for advanced imaging, and vague coverage policies for specialized neurological therapies creates barriers at every stage—from initial appointments to diagnostic testing to ongoing treatment. The evidence is clear: these delays cost more money overall and produce worse health outcomes than the upfront investment in timely neurological care.
If you’re facing insurance barriers to neurological care, start by requesting written pre-authorization for any recommended diagnostic imaging or specialist visits, obtain denial reasons in writing if claims are rejected, and consider filing appeals or seeking advocacy support from disease-specific organizations. Your state’s Department of Insurance may also investigate complaints about unreasonable denial patterns, and some neurologists’ offices have insurance specialists who help families appeal denials. The goal is not to blame insurance companies individually but to recognize a systemic problem and navigate it with documentation and persistence until you receive the care you need.
Frequently Asked Questions
What should I do if insurance denies imaging my neurologist recommended?
Request the specific reason for denial in writing. Common denials cite “lack of medical necessity”—ask your neurologist to provide clinical justification and submit an appeal with detailed documentation of your symptoms and why the imaging is necessary for diagnosis. If the appeal fails, check whether your state has external review processes for insurance disputes.
Is it worth pursuing out-of-network neurologists despite higher denial rates?
Only if your in-network options have unacceptable wait times (typically over three months) or limited expertise in your specific condition. Before going out-of-network, request pre-authorization in writing and get a cost estimate. Budget for potential out-of-pocket costs if denial occurs.
How can I find out what my plan actually covers for neurological care?
Call your insurance company and ask specifically about coverage for diagnostic imaging (MRI, PET, EEG), specialist neurologist visits, and any neurological therapies relevant to your condition. Request written confirmation of coverage limits and any prior authorization requirements. Many plans have limited transparency, so written confirmation protects you.
If my ACA subsidies ended in 2025, what are my options for 2026?
Review marketplace plans for 2026 during open enrollment or if you’ve experienced a qualifying life event. Some families qualify for state-level assistance programs or Medicaid depending on income. Non-profit organizations focused on neurological diseases sometimes offer financial assistance for care costs.
Can I appeal an imaging denial if my doctor says it’s medically necessary?
Yes. Ask your doctor’s office to file an appeal with detailed clinical justification. If the first appeal fails, request an external independent review through your state’s insurance commissioner or department. Keep detailed records of all denials, appeals, and correspondence.
You Might Also Like
- Transportation Infrastructure: The Hidden Key to Better Care Outcomes
- Transportation Infrastructure: The Hidden Key to Better Care Outcomes
- Why Proactive Intervention Becomes Essential in Dementia Care Strategy
For more, see Alzheimer’s Association — clinical trials.
